Eiji Matsuura

Prof. Eiji Matsuura

Neutron Therapy Research Center, Collaborative Research Center, Department of Cell Chemistry, Okayama University, Okayama 700-8558, Japan
orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1990 in The Lancet
Verified
Journal Article
Closed access
Eiji MatsuuraEiji Matsuura
Eiji Matsuura
YIYoshiko Igarashi
Yoshiko Igarashi
MFMasao Fujimoto
Masao Fujimoto
KIKenji Ichikawa
Kenji Ichikawa
TKTakao Koike
Takao Koike

22 November 2005 in Circulation
Verified
Journal Article
Closed access
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
RGRoberto Gerli
Roberto Gerli
ADAndrea Doria
Andrea Doria
Eiji MatsuuraEiji Matsuura
Eiji Matsuura
MCMarco Matucci Cerinic
Marco Matucci Cerinic
YSYaniv Sherer
Yaniv Sherer

1 February 1994 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
Eiji MatsuuraEiji Matsuura
Eiji Matsuura
YIY Igarashi
Y Igarashi
TYT Yasuda
T Yasuda
DTD A Triplett
D A Triplett
TKT Koike
T Koike
Anticardiolipin antibodies (aCL) derived from the sera of individuals exhibiting the antiphospholipid syndrome (APS) directly bind to beta 2-glycoprotein I (beta 2-GPI), which is adsorbed to an oxidized polystyrene surface. Oxygen atoms were introduced on a polystyrene surface by irradiation with electron or gamma-ray radiation. X-ray photoelectron spectroscopy revealed the irradiated surfaces were oxidized to generate C-O and C = O moieties. aCL derived from either APS patients or (NZW x BXSB)F1 mice bound to beta 2-GPI coated on the irradiated plates, depending on the radiation dose. Antibody binding to beta 2-GPI on the irradiated plates was competitively inhibited by simultaneous addition of cardiolipin (CL)-coated latex beads mixed together with beta 2-GPI but were unaffected by addition of excess beta 2-GPI, CL micelles, or CL-coated latex beads alone. There was a high correlation between binding values of aCL in sera from 40 APS patients obtained by the anti-beta 2-GPI enzyme-linked immunosorbent assay (ELISA) using the irradiated plates and those by the beta 2-GPI-dependent aCL ELISA. Therefore, aCL have specificity for an epitope on beta 2-GPI. This epitope is expressed by a conformational change occurring when beta 2-GPI interacts with an oxygen-substituted solid phase surface.

1 September 2000 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
TATatsuya Atsumi
Tatsuya Atsumi
MIMasahiro Ieko
Masahiro Ieko
MBMaria L. Bertolaccini
Maria L. Bertolaccini
KIKenji Ichikawa
Kenji Ichikawa
ATAkito Tsutsumi
Akito Tsutsumi
TKTakao Koike
Takao Koike
Objective To clarify the association of autoantibodies against prothrombin with the clinical manifestations of the antiphospholipid syndrome (APS) and with the presence of lupus anticoagulant (LAC). Methods We examined 265 patients who visited our autoimmune disease clinic. IgG and IgM antiprothrombin antibodies were tested by enzyme‐linked immunosorbent assay (ELISA) as either antiphosphatidylserine–prothrombin complex (aPS/PT) antibodies or as antibodies against prothrombin coated on irradiated ELISA plates (as antigen) (aPT). IgG, IgM, and IgA anticardiolipin (aCL) antibodies and their β2‐glycoprotein I (β2GPI) dependency were also evaluated by ELISA. LAC was tested by 3 different methods. Results The presence of aPS/PT, but not of aPT, significantly correlated with the clinical manifestations of APS (odds ratio [OR] 4.39, 95% confidence interval [95% CI] 2.06–9.38), and aPS/PT antibodies were as specific as β2GPI‐dependent aCL for APS (93.1% for both). IgG aPS/PT strongly correlated with the presence of LAC as detected using the dilute Russell viper venom time test (OR 38.2, 95% CI 13.4–109.1). Conclusion Antiprothrombin antibodies are heterogeneous and their clinical relevance depends on the method of detection applied. Positive results on the aPS/PT test can serve as a marker of thrombotic events in patients with autoimmune diseases.

1 December 1995 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
YHY Honda
Y Honda
YKY Kuroki
Y Kuroki
Eiji MatsuuraEiji Matsuura
Eiji Matsuura
HNH Nagae
H Nagae
HTH Takahashi
H Takahashi
SAS Abe
S Abe
Pulmonary surfactant protein D (SP-D) is a hydrophilic glycoprotein with a reduced molecular mass of 43 kDa and a member of the C-type lectin superfamily, along with mannose-binding proteins and surfactant protein A (SP-A). We have recently prepared monoclonal antibodies against human SP-D and developed an enzyme-linked immunosorbent assay (ELISA). In this study, the levels of SP-D in sera and bronchoalveolar lavage (BAL) fluids of patients with lung diseases were determined by ELISA, using human recombinant SP-D as a standard. We demonstrated that the concentrations of SP-D in sera are prominently increased in patients with idiopathic pulmonary fibrosis (IPF), interstitial pneumonia with collagen disease (IPCD), and pulmonary alveolar proteinosis (PAP). Patients with IPF, IPCD, and PAP exhibited levels of serum SP-D 5.1-fold, 7.2-fold, and 7.0-fold, respectively, of those in healthy volunteers; 91.5% of the patients with IPF, 81.3% with IPCD, and 100% with PAP exhibited serum SP-D levels that exceeded the cut-off value (mean + 2 SD of control value). Serum SP-D levels appeared to reflect the disease activity of IPF and IPCD and the disease severity of PAP. High levels of SP-D in BAL fluids were shown in patients with PAP, but not with IPF and IPCD. We conclude that measurement of SP-D in sera can provide an easily identifiable and useful clinical marker for the diagnosis of IPF, IPCD, and PAP, and can predict the disease activity of IPF and IPCD and the disease severity of PAP.

15 June 1992 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
Eiji MatsuuraEiji Matsuura
Eiji Matsuura
YIY Igarashi
Y Igarashi
MFM Fujimoto
M Fujimoto
KIK Ichikawa
K Ichikawa
TST Suzuki
T Suzuki
TKT Koike
T Koike
Anticardiolipin antibodies (aCL) found in sera from patients with SLE react with cardiolipin (CL) in the presence of a 50-kDa serum cofactor. The cofactor, which was identified to be beta 2-glycoprotein I by sequencing the N-terminal amino acids, not only enhances CL binding by antibodies in SLE but also depresses it by antibodies associated with syphilis. Cofactor-dependent binding of aCL in SLE to solid phase CL was competitively inhibited by the simultaneous addition of fluid phase CL but was unaffected by either prior or simultaneous addition of a high excess of the cofactor. Binding of aCL in syphilis to solid phase CL was competitively inhibited by either addition of the cofactor or fluid phase CL. aCL in SLE reacted with CL, PS, and PA in the presence of cofactor. In contrast, biotinyl-cofactor bound directly to these anionic phospholipids (PL) and also to PG. These results show that the cofactor-CL complex bears an epitope that confers recognition specificity for aCL in SLE, in contrast with direct CL recognition by syphilitic aCL. The direct binding of the cofactor to PL suggests that the cofactor dependence of aCL binding to PL is due to recognition by aCL of a unique epitope generated upon the formation of the cofactor-CL complex.